EA014941B1 - АГЕНТЫ ДЛЯ ПРЕДУПРЕЖДЕНИЯ И ЛЕЧЕНИЯ НАРУШЕНИЙ, ВКЛЮЧАЮЩИХ МОДУЛИРОВАНИЕ RyR РЕЦЕПТОРОВ - Google Patents

Info

Publication number

EA014941B1

EA014941B1 EA200800665A EA200800665A EA014941B1 EA 014941 B1 EA014941 B1 EA 014941B1 EA 200800665 A EA200800665 A EA 200800665A EA 200800665 A EA200800665 A EA 200800665A EA 014941 B1 EA014941 B1 EA 014941B1

Authority

EA

Eurasian Patent Office

Prior art keywords

alkyl

formula

aryl

disorders

cycloalkyl

Prior art date

2005-08-25

Links

• Espacenet
• Global Dossier
• Discuss

• 230000003405 preventing effect Effects 0.000 title description 49
• 150000001875 compounds Chemical class 0.000 claims abstract description 367
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 199
• 208000035475 disorder Diseases 0.000 claims abstract description 104
• 238000000034 method Methods 0.000 claims abstract description 102
• 201000010099 disease Diseases 0.000 claims abstract description 95
• 150000003839 salts Chemical class 0.000 claims abstract description 73
• 239000012453 solvate Substances 0.000 claims abstract description 45
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
• 102000003922 Calcium Channels Human genes 0.000 claims abstract description 13
• 108090000312 Calcium Channels Proteins 0.000 claims abstract description 13
• 125000003118 aryl group Chemical group 0.000 claims description 277
• 125000000217 alkyl group Chemical group 0.000 claims description 262
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 226
• 125000000623 heterocyclic group Chemical group 0.000 claims description 226
• 125000003342 alkenyl group Chemical group 0.000 claims description 181
• 125000005842 heteroatom Chemical group 0.000 claims description 167
• 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 156
• 125000002252 acyl group Chemical group 0.000 claims description 122
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 118
• 125000003282 alkyl amino group Chemical group 0.000 claims description 112
• 239000002904 solvent Substances 0.000 claims description 105
• 125000003545 alkoxy group Chemical group 0.000 claims description 102
• 229910052736 halogen Inorganic materials 0.000 claims description 78
• 150000002367 halogens Chemical class 0.000 claims description 77
• 210000002027 skeletal muscle Anatomy 0.000 claims description 76
• 125000001072 heteroaryl group Chemical group 0.000 claims description 67
• 229910052739 hydrogen Inorganic materials 0.000 claims description 67
• 125000000304 alkynyl group Chemical group 0.000 claims description 61
• 206010019280 Heart failures Diseases 0.000 claims description 55
• -1 -O8 (= O) 2CE3 Chemical group 0.000 claims description 50
• 125000005110 aryl thio group Chemical group 0.000 claims description 50
• 230000034994 death Effects 0.000 claims description 43
• 231100000517 death Toxicity 0.000 claims description 43
• 230000001269 cardiogenic effect Effects 0.000 claims description 39
• 208000019622 heart disease Diseases 0.000 claims description 36
• 230000001746 atrial effect Effects 0.000 claims description 35
• 230000000747 cardiac effect Effects 0.000 claims description 35
• 125000001769 aryl amino group Chemical group 0.000 claims description 34
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 30
• 239000000243 solution Substances 0.000 claims description 30
• 206010047302 ventricular tachycardia Diseases 0.000 claims description 28
• 125000004414 alkyl thio group Chemical group 0.000 claims description 25
• 239000003795 chemical substances by application Substances 0.000 claims description 25
• 206010049565 Muscle fatigue Diseases 0.000 claims description 24
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 24
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 23
• 125000004122 cyclic group Chemical group 0.000 claims description 22
• 229910052757 nitrogen Inorganic materials 0.000 claims description 22
• 239000003814 drug Substances 0.000 claims description 17
• 206010003658 Atrial Fibrillation Diseases 0.000 claims description 16
• 239000002253 acid Substances 0.000 claims description 16
• 206010003130 Arrhythmia supraventricular Diseases 0.000 claims description 15
• 208000000044 Amnesia Diseases 0.000 claims description 14
• 208000026139 Memory disease Diseases 0.000 claims description 14
• 230000001788 irregular Effects 0.000 claims description 14
• 230000006984 memory degeneration Effects 0.000 claims description 14
• 208000023060 memory loss Diseases 0.000 claims description 14
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 13
• 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 13
• 150000007657 benzothiazepines Chemical group 0.000 claims description 13
• 230000002285 radioactive effect Effects 0.000 claims description 13
• 229910052700 potassium Inorganic materials 0.000 claims description 12
• 230000015572 biosynthetic process Effects 0.000 claims description 11
• 201000000015 catecholaminergic polymorphic ventricular tachycardia Diseases 0.000 claims description 11
• 238000001990 intravenous administration Methods 0.000 claims description 11
• 230000002265 prevention Effects 0.000 claims description 11
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 11
• 208000003663 ventricular fibrillation Diseases 0.000 claims description 11
• 206010042434 Sudden death Diseases 0.000 claims description 10
• 229910052799 carbon Inorganic materials 0.000 claims description 10
• 230000003993 interaction Effects 0.000 claims description 10
• 230000005856 abnormality Effects 0.000 claims description 9
• 150000001412 amines Chemical class 0.000 claims description 9
• 201000006938 muscular dystrophy Diseases 0.000 claims description 9
• 208000020446 Cardiac disease Diseases 0.000 claims description 8
• 206010007559 Cardiac failure congestive Diseases 0.000 claims description 8
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 8
• 206010020772 Hypertension Diseases 0.000 claims description 8
• 206010003668 atrial tachycardia Diseases 0.000 claims description 8
• 239000000872 buffer Substances 0.000 claims description 8
• 125000004432 carbon atom Chemical group C* 0.000 claims description 8
• 230000003930 cognitive ability Effects 0.000 claims description 8
• 238000004519 manufacturing process Methods 0.000 claims description 8
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
• 208000024827 Alzheimer disease Diseases 0.000 claims description 7
• 206010020844 Hyperthermia malignant Diseases 0.000 claims description 7
• 206010021639 Incontinence Diseases 0.000 claims description 7
• 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 claims description 7
• 206010012601 diabetes mellitus Diseases 0.000 claims description 7
• 201000007004 malignant hyperthermia Diseases 0.000 claims description 7
• 208000011580 syndromic disease Diseases 0.000 claims description 7
• 206010065341 Ventricular tachyarrhythmia Diseases 0.000 claims description 6
• 239000003085 diluting agent Substances 0.000 claims description 6
• 229920006395 saturated elastomer Polymers 0.000 claims description 6
• 239000004215 Carbon black (E152) Substances 0.000 claims description 5
• 239000008187 granular material Substances 0.000 claims description 5
• 229930195733 hydrocarbon Natural products 0.000 claims description 5
• 150000002430 hydrocarbons Chemical class 0.000 claims description 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
• UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 5
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
• 239000011230 binding agent Substances 0.000 claims description 4
• 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 4
• 239000007884 disintegrant Substances 0.000 claims description 4
• 239000000843 powder Substances 0.000 claims description 4
• 239000003963 antioxidant agent Substances 0.000 claims description 3
• 239000002775 capsule Substances 0.000 claims description 3
• 239000000969 carrier Substances 0.000 claims description 3
• 239000003086 colorant Substances 0.000 claims description 3
• 239000003995 emulsifying agent Substances 0.000 claims description 3
• 239000000945 filler Substances 0.000 claims description 3
• 239000000796 flavoring agent Substances 0.000 claims description 3
• 235000013355 food flavoring agent Nutrition 0.000 claims description 3
• 235000003599 food sweetener Nutrition 0.000 claims description 3
• 238000007918 intramuscular administration Methods 0.000 claims description 3
• 230000035515 penetration Effects 0.000 claims description 3
• 239000003755 preservative agent Substances 0.000 claims description 3
• 239000003381 stabilizer Substances 0.000 claims description 3
• 239000000375 suspending agent Substances 0.000 claims description 3
• 239000000725 suspension Substances 0.000 claims description 3
• 239000003765 sweetening agent Substances 0.000 claims description 3
• 125000002619 bicyclic group Chemical group 0.000 claims description 2
• 150000004820 halides Chemical class 0.000 claims description 2
• 125000002950 monocyclic group Chemical group 0.000 claims description 2
• 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
• 229930195734 saturated hydrocarbon Natural products 0.000 claims description 2
• 159000000000 sodium salts Chemical group 0.000 claims description 2
• 125000004434 sulfur atom Chemical group 0.000 claims description 2
• 230000002861 ventricular Effects 0.000 claims description 2
• 230000010247 heart contraction Effects 0.000 claims 8
• 239000003623 enhancer Substances 0.000 claims 4
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 2
• 239000003349 gelling agent Substances 0.000 claims 2
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims 1
• ZGGBEERDYFLGPW-UHFFFAOYSA-N 3-(3,5-dihydro-2h-1,4-benzothiazepin-4-yl)-1-phenylpropan-1-one Chemical compound C1CSC2=CC=CC=C2CN1CCC(=O)C1=CC=CC=C1 ZGGBEERDYFLGPW-UHFFFAOYSA-N 0.000 claims 1
• NQUVGDWEWBRNAY-UHFFFAOYSA-N 4-(diethoxyphosphorylmethyl)-3,5-dihydro-2H-1,4-benzothiazepine Chemical compound C1N(CP(=O)(OCC)OCC)CCSC2=CC=CC=C21 NQUVGDWEWBRNAY-UHFFFAOYSA-N 0.000 claims 1
• WLJDAPBDQIXNAI-UHFFFAOYSA-N 4-[(4-chlorophenyl)methyl]-3,5-dihydro-2h-1,4-benzothiazepine Chemical compound C1=CC(Cl)=CC=C1CN1CC2=CC=CC=C2SCC1 WLJDAPBDQIXNAI-UHFFFAOYSA-N 0.000 claims 1
• KWFXDSKKCIWDFV-UHFFFAOYSA-N 4-[(4-methoxyphenyl)methyl]-3,5-dihydro-2h-1,4-benzothiazepine Chemical compound C1=CC(OC)=CC=C1CN1CC2=CC=CC=C2SCC1 KWFXDSKKCIWDFV-UHFFFAOYSA-N 0.000 claims 1
• XRHNTUDLOFKUFB-UHFFFAOYSA-N 4-ethylsulfonyl-3,5-dihydro-2h-1,4-benzothiazepine Chemical compound C1N(S(=O)(=O)CC)CCSC2=CC=CC=C21 XRHNTUDLOFKUFB-UHFFFAOYSA-N 0.000 claims 1
• MVONUVDATWXOLI-UHFFFAOYSA-N 4-methylsulfonyl-3,5-dihydro-2h-1$l^{4},4-benzothiazepine 1-oxide Chemical compound C1N(S(=O)(=O)C)CCS(=O)C2=CC=CC=C21 MVONUVDATWXOLI-UHFFFAOYSA-N 0.000 claims 1
• GQKWMROFTREIMB-UHFFFAOYSA-N 4-methylsulfonyl-3,5-dihydro-2h-1,4-benzothiazepine Chemical compound C1N(S(=O)(=O)C)CCSC2=CC=CC=C21 GQKWMROFTREIMB-UHFFFAOYSA-N 0.000 claims 1
• YJWORHPBMHBZEI-UHFFFAOYSA-N 4-pentyl-3,5-dihydro-2h-1,4-benzothiazepine Chemical compound C1N(CCCCC)CCSC2=CC=CC=C21 YJWORHPBMHBZEI-UHFFFAOYSA-N 0.000 claims 1
• 239000006172 buffering agent Substances 0.000 claims 1
• 125000005843 halogen group Chemical group 0.000 claims 1
• 239000003826 tablet Substances 0.000 claims 1
• 239000000651 prodrug Substances 0.000 abstract description 46
• 229940002612 prodrug Drugs 0.000 abstract description 46
• 150000004677 hydrates Chemical class 0.000 abstract description 41
• 230000002194 synthesizing effect Effects 0.000 abstract 1
• 108091006146 Channels Proteins 0.000 description 133
• 241000699670 Mus sp. Species 0.000 description 98
• 239000011575 calcium Substances 0.000 description 97
• 210000004027 cell Anatomy 0.000 description 97
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 87
• 230000005764 inhibitory process Effects 0.000 description 72
• 239000011541 reaction mixture Substances 0.000 description 70
• 238000006243 chemical reaction Methods 0.000 description 63
• 239000003960 organic solvent Substances 0.000 description 58
• 230000000694 effects Effects 0.000 description 56
• 239000000047 product Substances 0.000 description 56
• 125000002877 alkyl aryl group Chemical group 0.000 description 53
• 238000006366 phosphorylation reaction Methods 0.000 description 52
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 51
• 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 50
• 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 50
• 101001060736 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP1B Proteins 0.000 description 49
• 102100027914 Peptidyl-prolyl cis-trans isomerase FKBP1B Human genes 0.000 description 49
• 101001060732 Rattus norvegicus Peptidyl-prolyl cis-trans isomerase FKBP1B Proteins 0.000 description 49
• 230000001965 increasing effect Effects 0.000 description 49
• 206010003119 arrhythmia Diseases 0.000 description 46
• 230000027455 binding Effects 0.000 description 46
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 46
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 43
• 230000026731 phosphorylation Effects 0.000 description 43
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
• 230000007423 decrease Effects 0.000 description 38
• 239000000203 mixture Substances 0.000 description 32
• 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 31
• 101710111682 Peptidyl-prolyl cis-trans isomerase FKBP1A Proteins 0.000 description 31
• 241001465754 Metazoa Species 0.000 description 30
• 230000003834 intracellular effect Effects 0.000 description 30
• 108020003175 receptors Proteins 0.000 description 30
• 102000005962 receptors Human genes 0.000 description 30
• 230000002829 reductive effect Effects 0.000 description 30
• 239000003054 catalyst Substances 0.000 description 29
• 108090000623 proteins and genes Proteins 0.000 description 29
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 28
• 125000002757 morpholinyl group Chemical group 0.000 description 27
• 235000018102 proteins Nutrition 0.000 description 27
• 102000004169 proteins and genes Human genes 0.000 description 27
• 238000000746 purification Methods 0.000 description 27
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 26
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
• 101100341096 Caenorhabditis elegans pyp-1 gene Proteins 0.000 description 24
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 21
• 238000004440 column chromatography Methods 0.000 description 21
• 238000003119 immunoblot Methods 0.000 description 21
• 210000001519 tissue Anatomy 0.000 description 21
• 230000004913 activation Effects 0.000 description 20
• 239000002585 base Substances 0.000 description 20
• 230000004044 response Effects 0.000 description 20
• 241000699666 Mus <mouse, genus> Species 0.000 description 18
• 210000003205 muscle Anatomy 0.000 description 18
• 150000003254 radicals Chemical class 0.000 description 18
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 17
• 229910052791 calcium Inorganic materials 0.000 description 17
• 230000035772 mutation Effects 0.000 description 17
• 229940079593 drug Drugs 0.000 description 16
• 238000003786 synthesis reaction Methods 0.000 description 16
• 239000003153 chemical reaction reagent Substances 0.000 description 15
• 208000010125 myocardial infarction Diseases 0.000 description 15
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 15
• 239000003637 basic solution Substances 0.000 description 14
• 239000000902 placebo Substances 0.000 description 14
• 229940068196 placebo Drugs 0.000 description 14
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
• 230000006793 arrhythmia Effects 0.000 description 13
• 239000013256 coordination polymer Substances 0.000 description 13
• 230000001419 dependent effect Effects 0.000 description 13
• 238000002156 mixing Methods 0.000 description 13
• 230000002035 prolonged effect Effects 0.000 description 13
• 238000012360 testing method Methods 0.000 description 13
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 12
• 125000005354 acylalkyl group Chemical group 0.000 description 12
• 239000000975 dye Substances 0.000 description 12
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
• 239000000543 intermediate Substances 0.000 description 12
• 210000001087 myotubule Anatomy 0.000 description 12
• 125000004043 oxo group Chemical group O=* 0.000 description 12
• BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 12
• 238000004587 chromatography analysis Methods 0.000 description 11
• 230000002950 deficient Effects 0.000 description 11
• 230000006951 hyperphosphorylation Effects 0.000 description 11
• 229910052740 iodine Inorganic materials 0.000 description 11
• 230000009182 swimming Effects 0.000 description 11
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 10
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
• 238000004458 analytical method Methods 0.000 description 10
• 238000002347 injection Methods 0.000 description 10
• 239000007924 injection Substances 0.000 description 10
• 210000004165 myocardium Anatomy 0.000 description 10
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
• 239000003929 acidic solution Substances 0.000 description 9
• 210000004413 cardiac myocyte Anatomy 0.000 description 9
• 239000000460 chlorine Substances 0.000 description 9
• 208000010877 cognitive disease Diseases 0.000 description 9
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 9
• 239000000741 silica gel Substances 0.000 description 9
• 229910002027 silica gel Inorganic materials 0.000 description 9
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
• 241000700159 Rattus Species 0.000 description 8
• 230000002378 acidificating effect Effects 0.000 description 8
• 239000007864 aqueous solution Substances 0.000 description 8
• 230000006870 function Effects 0.000 description 8
• 239000012044 organic layer Substances 0.000 description 8
• 230000036470 plasma concentration Effects 0.000 description 8
• 238000002360 preparation method Methods 0.000 description 8
• 108090000765 processed proteins & peptides Proteins 0.000 description 8
• 230000009467 reduction Effects 0.000 description 8
• 208000013363 skeletal muscle disease Diseases 0.000 description 8
• 235000017557 sodium bicarbonate Nutrition 0.000 description 8
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
• 230000000087 stabilizing effect Effects 0.000 description 8
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
• 230000005540 biological transmission Effects 0.000 description 7
• 230000001086 cytosolic effect Effects 0.000 description 7
• 238000010494 dissociation reaction Methods 0.000 description 7
• 230000005593 dissociations Effects 0.000 description 7
• 239000003937 drug carrier Substances 0.000 description 7
• 230000000670 limiting effect Effects 0.000 description 7
• 239000012047 saturated solution Substances 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 238000005406 washing Methods 0.000 description 7
• QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 6
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 6
• 229930182837 (R)-adrenaline Natural products 0.000 description 6
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 6
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 6
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 6
• 208000021642 Muscular disease Diseases 0.000 description 6
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
• 238000003556 assay Methods 0.000 description 6
• 210000004351 coronary vessel Anatomy 0.000 description 6
• 230000007547 defect Effects 0.000 description 6
• 230000008021 deposition Effects 0.000 description 6
• 238000000151 deposition Methods 0.000 description 6
• 229960005139 epinephrine Drugs 0.000 description 6
• GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 6
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 6
• 238000007912 intraperitoneal administration Methods 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 239000012071 phase Substances 0.000 description 6
• 150000004032 porphyrins Chemical class 0.000 description 6
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 6
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
• 230000001105 regulatory effect Effects 0.000 description 6
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 6
• 239000007858 starting material Substances 0.000 description 6
• 125000001424 substituent group Chemical group 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 6
• 239000004475 Arginine Substances 0.000 description 5
• 102000001039 Dystrophin Human genes 0.000 description 5
• 108010069091 Dystrophin Proteins 0.000 description 5
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
• 230000002159 abnormal effect Effects 0.000 description 5
• 230000002547 anomalous effect Effects 0.000 description 5
• 239000008346 aqueous phase Substances 0.000 description 5
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
• ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 5
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
• 235000001671 coumarin Nutrition 0.000 description 5
• 150000004775 coumarins Chemical class 0.000 description 5
• 210000000805 cytoplasm Anatomy 0.000 description 5
• 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 5
• 238000001035 drying Methods 0.000 description 5
• 230000004064 dysfunction Effects 0.000 description 5
• 238000001704 evaporation Methods 0.000 description 5
• 239000012467 final product Substances 0.000 description 5
• 230000003287 optical effect Effects 0.000 description 5
• 230000036961 partial effect Effects 0.000 description 5
• 238000012545 processing Methods 0.000 description 5
• 238000004445 quantitative analysis Methods 0.000 description 5
• 230000001603 reducing effect Effects 0.000 description 5
• 238000000926 separation method Methods 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• KYVHGCKMVJDCNV-UHFFFAOYSA-N 1,4-benzothiazepine Chemical class S1C=CN=CC2=CC=CC=C12 KYVHGCKMVJDCNV-UHFFFAOYSA-N 0.000 description 4
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
• 239000004698 Polyethylene Substances 0.000 description 4
• 125000004947 alkyl aryl amino group Chemical group 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 230000000903 blocking effect Effects 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 210000000170 cell membrane Anatomy 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 230000001684 chronic effect Effects 0.000 description 4
• 230000008602 contraction Effects 0.000 description 4
• 238000012937 correction Methods 0.000 description 4
• 229940099500 cystamine Drugs 0.000 description 4
• 230000007850 degeneration Effects 0.000 description 4
• 230000008020 evaporation Effects 0.000 description 4
• 210000002064 heart cell Anatomy 0.000 description 4
• 230000001976 improved effect Effects 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 229910052745 lead Inorganic materials 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 230000028161 membrane depolarization Effects 0.000 description 4
• 230000004118 muscle contraction Effects 0.000 description 4
• 230000003387 muscular Effects 0.000 description 4
• 239000013642 negative control Substances 0.000 description 4
• 230000002085 persistent effect Effects 0.000 description 4
• 238000013031 physical testing Methods 0.000 description 4
• 229920001184 polypeptide Polymers 0.000 description 4
• 102000004196 processed proteins & peptides Human genes 0.000 description 4
• 229910052938 sodium sulfate Inorganic materials 0.000 description 4
• 235000011152 sodium sulphate Nutrition 0.000 description 4
• 238000010561 standard procedure Methods 0.000 description 4
• 230000001225 therapeutic effect Effects 0.000 description 4
• NBOOZXVYXHATOW-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-ylmethyl)piperazine Chemical compound C=1C=C2OCOC2=CC=1CN1CCNCC1 NBOOZXVYXHATOW-UHFFFAOYSA-N 0.000 description 3
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 3
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
• 241000282472 Canis lupus familiaris Species 0.000 description 3
• 229920002261 Corn starch Polymers 0.000 description 3
• 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 3
• 208000028782 Hereditary disease Diseases 0.000 description 3
• 208000029578 Muscle disease Diseases 0.000 description 3
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
• 102000035195 Peptidases Human genes 0.000 description 3
• 108091005804 Peptidases Proteins 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 239000004365 Protease Substances 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
• 210000001124 body fluid Anatomy 0.000 description 3
• 239000010839 body fluid Substances 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 239000001913 cellulose Substances 0.000 description 3
• 229920002678 cellulose Polymers 0.000 description 3
• 235000010980 cellulose Nutrition 0.000 description 3
• 239000007795 chemical reaction product Substances 0.000 description 3
• 239000008120 corn starch Substances 0.000 description 3
• 238000002425 crystallisation Methods 0.000 description 3
• 230000008025 crystallization Effects 0.000 description 3
• 210000004748 cultured cell Anatomy 0.000 description 3
• 230000006735 deficit Effects 0.000 description 3
• 230000003205 diastolic effect Effects 0.000 description 3
• 238000000605 extraction Methods 0.000 description 3
• 239000000835 fiber Substances 0.000 description 3
• 239000007850 fluorescent dye Substances 0.000 description 3
• 239000001257 hydrogen Substances 0.000 description 3
• 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
• 238000003384 imaging method Methods 0.000 description 3
• 239000010410 layer Substances 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 229910017604 nitric acid Inorganic materials 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 208000014321 polymorphic ventricular tachycardia Diseases 0.000 description 3
• 238000001556 precipitation Methods 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• 125000006239 protecting group Chemical group 0.000 description 3
• 230000002336 repolarization Effects 0.000 description 3
• 230000000284 resting effect Effects 0.000 description 3
• 230000035945 sensitivity Effects 0.000 description 3
• 238000004088 simulation Methods 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 210000002820 sympathetic nervous system Anatomy 0.000 description 3
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
• KBTLDMSFADPKFJ-UHFFFAOYSA-N 2-phenyl-1H-indole-3,4-dicarboximidamide Chemical compound N1C2=CC=CC(C(N)=N)=C2C(C(=N)N)=C1C1=CC=CC=C1 KBTLDMSFADPKFJ-UHFFFAOYSA-N 0.000 description 2
• 244000215068 Acacia senegal Species 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 102000007590 Calpain Human genes 0.000 description 2
• 108010032088 Calpain Proteins 0.000 description 2
• 206010007558 Cardiac failure chronic Diseases 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 241000700199 Cavia porcellus Species 0.000 description 2
• 208000032862 Clinical Deterioration Diseases 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 229920000084 Gum arabic Polymers 0.000 description 2
• 241000728904 Iais Species 0.000 description 2
• 208000026350 Inborn Genetic disease Diseases 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 239000000232 Lipid Bilayer Substances 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 208000029549 Muscle injury Diseases 0.000 description 2
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 2
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
• 208000001871 Tachycardia Diseases 0.000 description 2
• 235000010489 acacia gum Nutrition 0.000 description 2
• 239000000205 acacia gum Substances 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 229940024606 amino acid Drugs 0.000 description 2
• 235000001014 amino acid Nutrition 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• 125000004103 aminoalkyl group Chemical group 0.000 description 2
• 239000003416 antiarrhythmic agent Substances 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
• 230000002457 bidirectional effect Effects 0.000 description 2
• 108091008324 binding proteins Proteins 0.000 description 2
• 230000005824 bladder abnormality Effects 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 239000012267 brine Substances 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 150000003943 catecholamines Chemical class 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 230000001149 cognitive effect Effects 0.000 description 2
• 239000000306 component Substances 0.000 description 2
• 230000008828 contractile function Effects 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 125000000392 cycloalkenyl group Chemical group 0.000 description 2
• OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 230000001687 destabilization Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 238000002405 diagnostic procedure Methods 0.000 description 2
• 208000037765 diseases and disorders Diseases 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 210000003754 fetus Anatomy 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 238000000799 fluorescence microscopy Methods 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 230000004217 heart function Effects 0.000 description 2
• 210000005003 heart tissue Anatomy 0.000 description 2
• 230000036732 histological change Effects 0.000 description 2
• 150000002433 hydrophilic molecules Chemical class 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 230000002527 hyperadrenergic effect Effects 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 238000007917 intracranial administration Methods 0.000 description 2
• 238000007913 intrathecal administration Methods 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 238000011813 knockout mouse model Methods 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 231100001231 less toxic Toxicity 0.000 description 2
• 231100000518 lethal Toxicity 0.000 description 2
• 230000001665 lethal effect Effects 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
• 235000019341 magnesium sulphate Nutrition 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• ZXUQEPZWVQIOJE-UHFFFAOYSA-N methyl 2-chloro-2-oxoacetate Chemical compound COC(=O)C(Cl)=O ZXUQEPZWVQIOJE-UHFFFAOYSA-N 0.000 description 2
• 210000000663 muscle cell Anatomy 0.000 description 2
• 230000004220 muscle function Effects 0.000 description 2
• 230000002107 myocardial effect Effects 0.000 description 2
• AJNFQUKPBCGJKX-UHFFFAOYSA-N n-[4-[1-[2-(6-methylpyridin-2-yl)ethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide;dihydrate;dihydrochloride Chemical compound O.O.Cl.Cl.CC1=CC=CC(CCN2CCC(CC2)C(=O)C=2C=CC(NS(C)(=O)=O)=CC=2)=N1 AJNFQUKPBCGJKX-UHFFFAOYSA-N 0.000 description 2
• HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
• 229960001597 nifedipine Drugs 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• 230000003204 osmotic effect Effects 0.000 description 2
• 125000000160 oxazolidinyl group Chemical group 0.000 description 2
• 125000002971 oxazolyl group Chemical group 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 230000003950 pathogenic mechanism Effects 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 239000003208 petroleum Substances 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
• 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 2
• HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
• 230000037081 physical activity Effects 0.000 description 2
• 230000008092 positive effect Effects 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 229920001592 potato starch Polymers 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 238000000159 protein binding assay Methods 0.000 description 2
• 125000000714 pyrimidinyl group Chemical group 0.000 description 2
• 238000010992 reflux Methods 0.000 description 2
• 239000011435 rock Substances 0.000 description 2
• 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 238000004904 shortening Methods 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 210000002363 skeletal muscle cell Anatomy 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 210000003699 striated muscle Anatomy 0.000 description 2
• 210000002948 striated muscle cell Anatomy 0.000 description 2
• 230000002889 sympathetic effect Effects 0.000 description 2
• 206010042772 syncope Diseases 0.000 description 2
• 238000001308 synthesis method Methods 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 229940033134 talc Drugs 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 125000001544 thienyl group Chemical group 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• HZDNNJABYXNPPV-UHFFFAOYSA-N (2-chloro-2-oxoethyl) acetate Chemical compound CC(=O)OCC(Cl)=O HZDNNJABYXNPPV-UHFFFAOYSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 description 1
• BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• FKJSFKCZZIXQIP-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=C(Br)C=C1 FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• 125000004610 3,4-dihydro-4-oxo-quinazolinyl group Chemical group O=C1NC(=NC2=CC=CC=C12)* 0.000 description 1
• GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
• ZVEWFTICTSQBDM-UHFFFAOYSA-N 4-methylphenol Chemical group [CH2]C1=CC=C(O)C=C1 ZVEWFTICTSQBDM-UHFFFAOYSA-N 0.000 description 1
• 101150039504 6 gene Proteins 0.000 description 1
• XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 108010064733 Angiotensins Proteins 0.000 description 1
• 102000015427 Angiotensins Human genes 0.000 description 1
• 101100064323 Arabidopsis thaliana DTX47 gene Proteins 0.000 description 1
• 206010003830 Automatism Diseases 0.000 description 1
• 102000051819 Baculoviral IAP Repeat-Containing 3 Human genes 0.000 description 1
• 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 description 1
• 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 101100326430 Caenorhabditis elegans bub-1 gene Proteins 0.000 description 1
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 102000034573 Channels Human genes 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 208000028698 Cognitive impairment Diseases 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 102000002585 Contractile Proteins Human genes 0.000 description 1
• 108010068426 Contractile Proteins Proteins 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 101100499270 Drosophila melanogaster Diap1 gene Proteins 0.000 description 1
• 208000011345 Duchenne and Becker muscular dystrophy Diseases 0.000 description 1
• 206010013975 Dyspnoeas Diseases 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 101100272587 Gallus gallus ITA gene Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 208000010496 Heart Arrest Diseases 0.000 description 1
• 241001236294 Hebe Species 0.000 description 1
• 101000572820 Homo sapiens MICOS complex subunit MIC60 Proteins 0.000 description 1
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
• 101150032161 IAP1 gene Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000024556 Mendelian disease Diseases 0.000 description 1
• 241000289419 Metatheria Species 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• CJUMAFVKTCBCJK-UHFFFAOYSA-N N-benzyloxycarbonylglycine Chemical compound OC(=O)CNC(=O)OCC1=CC=CC=C1 CJUMAFVKTCBCJK-UHFFFAOYSA-N 0.000 description 1
• 101100381300 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) atp-5 gene Proteins 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 101100340782 Oryza sativa subsp. indica ILI1 gene Proteins 0.000 description 1
• 101100340783 Oryza sativa subsp. japonica BHLH154 gene Proteins 0.000 description 1
• 101710173782 Oxygen-evolving enhancer protein 1, chloroplastic Proteins 0.000 description 1
• 206010033557 Palpitations Diseases 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
• 229930001406 Ryanodine Natural products 0.000 description 1
• 101100404456 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YNK1 gene Proteins 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 102000011856 Utrophin Human genes 0.000 description 1
• 108010075653 Utrophin Proteins 0.000 description 1
• XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
• ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000001133 acceleration Effects 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 230000008649 adaptation response Effects 0.000 description 1
• 108060000200 adenylate cyclase Proteins 0.000 description 1
• 102000030621 adenylate cyclase Human genes 0.000 description 1
• 210000000577 adipose tissue Anatomy 0.000 description 1
• 230000016571 aggressive behavior Effects 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 150000001335 aliphatic alkanes Chemical class 0.000 description 1
• 150000001336 alkenes Chemical class 0.000 description 1
• 150000003973 alkyl amines Chemical group 0.000 description 1
• 239000002160 alpha blocker Substances 0.000 description 1
• 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 150000003868 ammonium compounds Chemical class 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 229940127219 anticoagulant drug Drugs 0.000 description 1
• 229940127218 antiplatelet drug Drugs 0.000 description 1
• 230000003126 arrythmogenic effect Effects 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 125000003725 azepanyl group Chemical group 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 101150056596 azin2 gene Proteins 0.000 description 1
• 125000004069 aziridinyl group Chemical group 0.000 description 1
• 150000007514 bases Chemical class 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 125000005870 benzindolyl group Chemical group 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 1
• 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 208000007469 bidirectional tachycardia Diseases 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000003851 biochemical process Effects 0.000 description 1
• 238000010170 biological method Methods 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 125000006267 biphenyl group Chemical group 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
• 229940003871 calcium ion Drugs 0.000 description 1
• 229910001424 calcium ion Inorganic materials 0.000 description 1
• 230000003913 calcium metabolism Effects 0.000 description 1
• 230000001964 calcium overload Effects 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 230000005792 cardiovascular activity Effects 0.000 description 1
• 239000002327 cardiovascular agent Substances 0.000 description 1
• 229940125692 cardiovascular agent Drugs 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 239000002800 charge carrier Substances 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 238000013375 chromatographic separation Methods 0.000 description 1
• 230000002057 chronotropic effect Effects 0.000 description 1
• 238000004140 cleaning Methods 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000001447 compensatory effect Effects 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 125000004093 cyano group Chemical group *C#N 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 230000003436 cytoskeletal effect Effects 0.000 description 1
• 230000002354 daily effect Effects 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000030609 dephosphorylation Effects 0.000 description 1
• 238000006209 dephosphorylation reaction Methods 0.000 description 1
• 210000001047 desmosome Anatomy 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
• 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
• 125000004609 dihydroquinazolinyl group Chemical group N1(CN=CC2=CC=CC=C12)* 0.000 description 1
• BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 125000005879 dioxolanyl group Chemical group 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 238000002592 echocardiography Methods 0.000 description 1
• 230000009177 electrical depolarization Effects 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 238000003818 flash chromatography Methods 0.000 description 1
• 238000007667 floating Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 238000002795 fluorescence method Methods 0.000 description 1
• 238000001215 fluorescent labelling Methods 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 230000007849 functional defect Effects 0.000 description 1
• 125000003838 furazanyl group Chemical group 0.000 description 1
• 125000004615 furo[2,3-b]pyridinyl group Chemical group O1C(=CC=2C1=NC=CC2)* 0.000 description 1
• 125000004613 furo[2,3-c]pyridinyl group Chemical group O1C(=CC=2C1=CN=CC2)* 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000009395 genetic defect Effects 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 238000010448 genetic screening Methods 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 125000005241 heteroarylamino group Chemical group 0.000 description 1
• 125000005368 heteroarylthio group Chemical group 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 102000046079 human IMMT Human genes 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 238000005984 hydrogenation reaction Methods 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 238000007654 immersion Methods 0.000 description 1
• 238000011532 immunohistochemical staining Methods 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 229910017053 inorganic salt Inorganic materials 0.000 description 1
• 239000004041 inotropic agent Substances 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 230000016507 interphase Effects 0.000 description 1
• 230000037041 intracellular level Effects 0.000 description 1
• 229940110676 inzo Drugs 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 210000005240 left ventricle Anatomy 0.000 description 1
• 238000000444 liquid chromatography-electrochemical detection Methods 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229910052751 metal Chemical class 0.000 description 1
• 239000002184 metal Chemical class 0.000 description 1
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000012022 methylating agents‎ Substances 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 208000016334 muscle symptom Diseases 0.000 description 1
• 210000003365 myofibril Anatomy 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 125000005244 neohexyl group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 239000012074 organic phase Substances 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 150000003891 oxalate salts Chemical class 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 230000036284 oxygen consumption Effects 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000037368 penetrate the skin Effects 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 239000005426 pharmaceutical component Substances 0.000 description 1
• 150000002989 phenols Chemical class 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
• 230000001011 phospho-antigenic effect Effects 0.000 description 1
• 102000005681 phospholamban Human genes 0.000 description 1
• 108010059929 phospholamban Proteins 0.000 description 1
• 235000011007 phosphoric acid Nutrition 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000010399 physical interaction Effects 0.000 description 1
• 238000000053 physical method Methods 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 230000008288 physiological mechanism Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
• 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
• 235000015320 potassium carbonate Nutrition 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• 244000144977 poultry Species 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 230000036278 prepulse Effects 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 229940043274 prophylactic drug Drugs 0.000 description 1
• 108020001580 protein domains Proteins 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 229940043437 protein kinase A inhibitor Drugs 0.000 description 1
• 239000012656 protein kinase A inhibitor Substances 0.000 description 1
• 108010065251 protein kinase modulator Proteins 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• PFZCOWLKXHIVII-UHFFFAOYSA-N pyridin-1-ium-1-amine Chemical compound N[N+]1=CC=CC=C1 PFZCOWLKXHIVII-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 208000022587 qualitative or quantitative defects of dystrophin Diseases 0.000 description 1
• 238000011158 quantitative evaluation Methods 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000003014 reinforcing effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 201000004193 respiratory failure Diseases 0.000 description 1
• 230000003938 response to stress Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• JJSYXNQGLHBRRK-SFEDZAPPSA-N ryanodine Chemical compound O([C@@H]1[C@]([C@@]2([C@]3(O)[C@]45O[C@@]2(O)C[C@]([C@]4(CC[C@H](C)[C@H]5O)O)(C)[C@@]31O)C)(O)C(C)C)C(=O)C1=CC=CN1 JJSYXNQGLHBRRK-SFEDZAPPSA-N 0.000 description 1
• 150000003870 salicylic acids Chemical class 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 210000002235 sarcomere Anatomy 0.000 description 1
• 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 238000010898 silica gel chromatography Methods 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
• 235000010288 sodium nitrite Nutrition 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
• 235000019345 sodium thiosulphate Nutrition 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 238000012289 standard assay Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 229940032147 starch Drugs 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 229960004793 sucrose Drugs 0.000 description 1
• 208000014221 sudden cardiac arrest Diseases 0.000 description 1
• 150000003460 sulfonic acids Chemical class 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000008700 sympathetic activation Effects 0.000 description 1
• 230000035488 systolic blood pressure Effects 0.000 description 1
• 230000006794 tachycardia Effects 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
• 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
• QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 238000000954 titration curve Methods 0.000 description 1
• 238000012549 training Methods 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• 150000003628 tricarboxylic acids Chemical class 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 210000005239 tubule Anatomy 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 239000013598 vector Substances 0.000 description 1
• 238000012795 verification Methods 0.000 description 1
• 230000003313 weakening effect Effects 0.000 description 1
• GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1